The FDA has approved updated COVID-19 vaccines for the 2026-2027 season from Moderna, Pfizer, and Novavax/Sanofi, with eligibility clearly tailored by age and health status.

Spikevax is authorized for ages 6 months to 64 with at least one high-risk condition and for all adults 65+, while mNEXSPIKE covers ages 12 to 64 with a high-risk condition and all adults 65+.

The updated vaccines are expected to ship in the coming days, with Spikevax already approved in several countries and mNEXSPIKE approved in Japan; broader regulatory reviews continue worldwide.

An accompanying commentary urges broader use of antivirals in pediatric influenza care, noting that around 40% of high-risk kids with flu may not receive antivirals.

The story comes from a local outlet focusing on rollout plans rather than new scientific findings.

Historical context includes shifts in vaccine advisory leadership, affecting consensus on vaccine use and coverage.

The piece is authored by a public health advocate affiliated with a foundation and calls for reversing approvals while linking to supporting organizations.

The CDC has not issued an official vaccine recommendation for this year, though major medical groups are broadly encouraging vaccination for high-risk individuals.

Medical organizations continue to endorse vaccination despite the lack of an official CDC position for the season.

The press release did not present specific immunogenicity or tolerability data for the XFG formulations.

The report highlights the ongoing public health impact of COVID-19, citing substantial outpatient visits and hospitalizations from the prior year.

Moderna’s CEO emphasizes the continuing threat and cites U.S. data on outpatient visits and hospitalizations from the previous year.